HUBUNGAN ANTARA DURASI PEMBERIAN HAART (HIGHLY ACTIVE ANTI RETROVIRAL THERAPY) DENGAN PENINGKATAN LEVEL CD4 PADA PASIEN HIV DEWASA
DOI:
https://doi.org/10.29303/jku.v2i3.64Abstrak
Latar Belakang: Dinamika CD4 dikaitkan dengan durasi pemberian HAART memiliki keberagaman antar individu, antar seting waktu dan tempat. Dinamika CD4 paska HAART merupakan faktor penting baik dalam evaluasi klinis pasien HIV dan kepentingan epidemiologis. Penelitian ini bertujuan melihat hubungan antara durasi pemberian HAART dengan peningkatan level CD4. Metodologi: Merupakan penelitian potong lintang dengan kriteria inklusi: 1. Usia pasien ≥18 tahun, pria dan wanita, 2. Memiliki angka CD4 pre ART (CD4 naïve) dan CD4 setelah ART, 3. Memiliki data CD4 naïve dan CD4 setelah HAART, 4. Memiliki selisih CD4 terakhir dengan CD4 naïve positif, dan 5. Memiliki kepatuhan berobat. Durasi pemberian HAART (bulan) dikelompokkan dalam kelompok waktu: 1) <12, 2) 12 – 23, 3) 24-36 dan 4) ≥ 36. Hasil: Sejumlah 68 pasien dievaluasi. Dari 68 pasien terdapat 18 pasien yang memenuhi kriteria inklusi. Distribusi kelompok durasi dari 18 pasien: 1) 4 (22,2%), 2) 3 (16,7%), 3) 6 (33,3%) dan 4) 5 (27,8%). Dengan multivariate analysis terdapat perbedaan antar kelompok durasi terapi yang bermakna terhadap peningkatan CD4 (p=0,033; ANOVA). Secara spesifik perbandingan antar kelompok diuji menggunakan LSD post hoc test pada kelompok 1 dan 2 tidak ada perbedaan yang bermakna (p=0,801) demikian juga kelompok 2 dan 3 (p=0,553) namun pada kelompok 3 dan 4 terdapat perbedaan yang bermakna (p=0.020). Kesimpulan: Hanya 26,5% pasien yang mengalami kenaikan level CD4. Kenaikan level CD4 dapat terlihat secara bermakna setelah 36 bulan terapi HAART. Kata kunci: HAART, CD4, antiretroviral therapyReferensi
1. Kemenkes RI. 2011. Pedoman Nasional Tatalaksana Klinis dan Terapi Antiretroviral Pada Orang Dewasa. Jakarta
2. Sabin CA, AN Phillips. Should HIV therapy be started at a CD4 cell count
above 350 cells/μl in asymptomatic HIV-1-infected patients? [Special
commentary]. Curr Opinion in Infectious Diseases: 2009. 22 (2):191-197
3. WHO. 2010. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach.– 2010 rev.
Austria
4. Depkes RI. 2007. Pedoman Nasional Terapi Antiretroviral, Edisi kedua.
Jakarta
5. Kaufmann GR, L Perrin, G Pantaleo, M Opravil, H Furrer, A Telenti et al for the Swiss HIV Cohort Study Group. CD4 TLymphocyte Recovery in Individuals
with Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years. Arch Intern Med. 2003;163:2187-2195
6. Binquet C, G Chêne, H Jacqmin-Gadda, V Journot, M Savès, D Lacoste, et al. Modeling Changes in CD4-positive TLymphocyte Counts after the Start of
Highly Active Antiretroviral Therapy and the Relation with Risk of Opportunistic Infections. Am J Epidemiol 2001;153:386–93
7. Erb P, M Battegay, W Zimmerli, M Rickenbach, M Egger, for the Swiss HIV
Cohort Study. Effect of Antiretroviral Therapy on Viral Load, CD4 Cell
Count, and Progression to Acquired Immunodeficiency Syndrome in a
Community Human Immunodeficiency Virus–Infected Cohort Arch Intern Med. 2000;160:1134-1140
8. Wardoyo EH, Hartono TS, Yunita R. Highly active antiretroviral therapy
(HAART) initiation to HIV patients with various CD4 levels. Poster Presentation in 6th National Symposium Indonesian Antimicrobial Resistance Watch, July, 2010. Jakarta.
9. Kelly M. 2004. HIV Immunopathology. In: Hoy J and S Lewin (Editor) HIV
Management in Australasia: a guide for clinical care. Australasian Society for HIV Medicine Inc. ASHM.
2. Sabin CA, AN Phillips. Should HIV therapy be started at a CD4 cell count
above 350 cells/μl in asymptomatic HIV-1-infected patients? [Special
commentary]. Curr Opinion in Infectious Diseases: 2009. 22 (2):191-197
3. WHO. 2010. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach.– 2010 rev.
Austria
4. Depkes RI. 2007. Pedoman Nasional Terapi Antiretroviral, Edisi kedua.
Jakarta
5. Kaufmann GR, L Perrin, G Pantaleo, M Opravil, H Furrer, A Telenti et al for the Swiss HIV Cohort Study Group. CD4 TLymphocyte Recovery in Individuals
with Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years. Arch Intern Med. 2003;163:2187-2195
6. Binquet C, G Chêne, H Jacqmin-Gadda, V Journot, M Savès, D Lacoste, et al. Modeling Changes in CD4-positive TLymphocyte Counts after the Start of
Highly Active Antiretroviral Therapy and the Relation with Risk of Opportunistic Infections. Am J Epidemiol 2001;153:386–93
7. Erb P, M Battegay, W Zimmerli, M Rickenbach, M Egger, for the Swiss HIV
Cohort Study. Effect of Antiretroviral Therapy on Viral Load, CD4 Cell
Count, and Progression to Acquired Immunodeficiency Syndrome in a
Community Human Immunodeficiency Virus–Infected Cohort Arch Intern Med. 2000;160:1134-1140
8. Wardoyo EH, Hartono TS, Yunita R. Highly active antiretroviral therapy
(HAART) initiation to HIV patients with various CD4 levels. Poster Presentation in 6th National Symposium Indonesian Antimicrobial Resistance Watch, July, 2010. Jakarta.
9. Kelly M. 2004. HIV Immunopathology. In: Hoy J and S Lewin (Editor) HIV
Management in Australasia: a guide for clinical care. Australasian Society for HIV Medicine Inc. ASHM.
Unduhan
Diterbitkan
2017-10-26
Cara Mengutip
Wardoyo, E. H., & Hartono, T. S. (2017). HUBUNGAN ANTARA DURASI PEMBERIAN HAART (HIGHLY ACTIVE ANTI RETROVIRAL THERAPY) DENGAN PENINGKATAN LEVEL CD4 PADA PASIEN HIV DEWASA. Baphomet University : Situs Slot Online Gacor Terbaik Hari Ini Server Thailand Gampang Maxwin 2024, 2(3). https://doi.org/10.29303/jku.v2i3.64
Terbitan
Bagian
Penelitian